Engrail Therapeutics
Precision Neuroscience. Transformational Therapies.
- Headquarters
- San Diego, California
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- engrail.com
- Total Funding
- $221.0M
- Last Round
- $157.0M Series BMar 2024
About
Engrail Therapeutics is a clinical-stage pharmaceutical company focused on developing precision-targeted neuroscience therapies for neuropsychiatric and neurodevelopmental diseases. Its pipeline includes ENX-102 (GABA-A PAM for generalized anxiety disorder) and ENX-104 (for major depressive disorder with anhedonia), both in Phase 2 trials. The company raised a $157M Series B in 2024 to advance its programs.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account